0001564590-22-018279.txt : 20220506 0001564590-22-018279.hdr.sgml : 20220506 20220505162913 ACCESSION NUMBER: 0001564590-22-018279 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220505 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220505 DATE AS OF CHANGE: 20220505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TIVITY HEALTH, INC. CENTRAL INDEX KEY: 0000704415 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 621117144 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19364 FILM NUMBER: 22896807 BUSINESS ADDRESS: STREET 1: 701 COOL SPRINGS BOULEVARD CITY: FRANKLIN STATE: TN ZIP: 37067 BUSINESS PHONE: 6156144929 MAIL ADDRESS: STREET 1: 701 COOL SPRINGS BOULEVARD CITY: FRANKLIN STATE: TN ZIP: 37067 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHWAYS, INC. DATE OF NAME CHANGE: 20170104 FORMER COMPANY: FORMER CONFORMED NAME: TIVITY HEALTH, INC DATE OF NAME CHANGE: 20161230 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHWAYS, INC DATE OF NAME CHANGE: 20060201 8-K 1 tvty-8k_20220505.htm 8-K tvty-8k_20220505.htm
false 0000704415 0000704415 2022-05-05 2022-05-05

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  May 5, 2022

 

TIVITY HEALTH, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-19364

 

62-1117144

(State or other jurisdiction
of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

701 Cool Springs Boulevard

Franklin, Tennessee

 

 

37067

(Address of principal executive offices)

 

(Zip Code)

 

(800) 869-5311

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common Stock - $.001 par value

 

TVTY

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

 


 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 


 

Item 2.02. Results of Operations and Financial Condition.

On May 5, 2022, Tivity Health, Inc. (the “Company”) issued a press release announcing earnings results for the quarter ended March 31, 2022, the text of which is attached hereto as Exhibit 99.1.

 

Item 8.01. Other Events.

The information set forth in Item 2.02 above is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

Exhibit 99.1

 

Press Release dated May 5, 2022

 

 

 

Exhibit 104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

TIVITY HEALTH, INC.

 

 

 

By: 

 

/s/ Adam Holland

 

 

 

Name: Adam Holland

 

 

 

Title: Chief Financial Officer

 

Date:  May 5, 2022

 

 

EX-99.1 2 tvty-ex991_33.htm EX-99.1 tvty-ex991_33.htm

Exhibit 99.1

 

 

 

TIVITY HEALTH REPORTS FIRST QUARTER 2022 RESULTS

 

NASHVILLE, Tenn. (May 5, 2022) - Tivity Health, Inc. (Nasdaq:TVTY) (the “Company”), a leading provider of healthy life-changing solutions, including SilverSneakers®, today announced financial results for the first quarter ended March 31, 2022.

 

Richard Ashworth, President and Chief Executive Officer, commented, “Tivity Health’s first quarter results were driven by our continued growth in physical and virtual visits and highlight the important and growing role our brands play in the lives of our members.  

 

First Quarter Highlights

 

Revenue from continuing operations increased 18.0% to $127.5 million during the first quarter of 2022, compared to $108.1 million for the first quarter of 2021;

 

Income from continuing operations was $0.6 million, which included a non-cash unrealized net loss of $22.4 million related to the Company’s equity ownership in Sharecare and a non-cash unrealized net gain of $4.3 million on de-designated interest rate swaps;

 

Adjusted EBITDA from continuing operations was $37.4 million, compared to $41.2 million in the first quarter of 2021;

 

In-person SilverSneakers visits totaled 16.9 million for the first quarter of 2022, compared to 11.2 million in the prior year, and 16.5 million for the fourth quarter of 2021;

 

Virtual visits were 1.1 million in the first quarter of 2022, an increase of 67% compared to the fourth quarter of 2021.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


TVTY Reports First Quarter Results

Page 2

May 5, 2022

 

 

First Quarter 2022 Financial Information

 

Dollars in millions, except per-share data

See pages 10-12 for a reconciliation of non-GAAP financial measures

 

 

Three Months Ended

March 31,

 

 

2022

2021

 

 

 

 

 

Revenues from Continuing Operations

$127.5

$108.1

 

Income from Continuing Operations (1)

$0.6

$19.9

 

Income from Continuing Operations Margin (1)

0.5%

18.5%

 

Adjusted EBITDA from Continuing Operations (2)

$37.4

$41.2

 

Adjusted EBITDA from Continuing Operations Margin (2)

29.3%

38.1%

 

Diluted Earnings Per Share from Continuing Operations (1)

$0.01

$0.40

 

Adjusted Diluted Earnings Per Share from Continuing Operations (2)

$0.40

$0.40

 

Cash Flows from Operating Activities

$37.0

$22.6

 

Free Cash Flow (2)

$32.9

$19.4

 

 

(1)

Results for the three months ended March 31, 2022 include an unrealized pretax loss of $22.4 million related to the Company’s equity ownership in Sharecare and an unrealized pretax gain of $5.7 million on de-designated interest rate swaps. There is no net tax impact on the loss related to the Company’s equity ownership in Sharecare due to the existence of valuation allowances for deferred tax assets related to capital loss carryforwards.

(2)

Adjusted EBITDA from continuing operations, adjusted EBITDA from continuing operations margin, adjusted earnings per diluted share from continuing operations, and free cash flow are non-GAAP financial measures. See pages 10-12 for a reconciliation of non-GAAP financial measures.

 

Revenues in the first quarter of 2022 of $127.5 million increased by $19.4 million, or approximately 18%, compared to the first quarter of 2021, primarily due to continued recovery from the COVID-19 pandemic. SilverSneakers revenue of $96.1 million increased by $16.3 million primarily due to an increase in revenue-generating visits, and Prime Fitness revenue of $25.0 million increased by $2.4 million primarily due to higher average monthly subscribers.  

 

Income from continuing operations for the first quarter of 2022 was $0.6 million, a decrease of $19.3 million compared to the first quarter of 2021.  The results for the first quarter of 2022 reflect a non-cash unrealized net loss of $22.4 million related to the Company’s equity ownership in Sharecare, based on fluctuations in Sharecare’s stock price, and a non-cash unrealized net gain of $4.3 million on de-designated interest rate swaps.

 

Adjusted EBITDA from continuing operations was $37.4 million for the first quarter of 2022, or 29.3% of revenues, compared to $41.2 million for the first quarter of 2021, or 38.1% of revenues.  The decrease in adjusted EBITDA as a percentage of revenues is primarily due to a lower mix of revenues from per-member-per-month fees for SilverSneakers coupled with an increase in fitness location visit costs for SilverSneakers and Prime Fitness due to an increase in participation levels.

 

 

 

 

 

 

 


TVTY Reports First Quarter Results

Page 3

May 5, 2022

 

 

Transaction with Stone Point Capital

 

On April 5, 2022, the Company entered into a definitive agreement to be acquired by funds managed by Stone Point Capital. Under the terms of the agreement, Tivity Health stockholders will receive $32.50 in cash per share at closing.  The transaction with Stone Point Capital creates immediate and substantial value for shareholders while ensuring the Company continues to help SilverSneakers members live healthier, happier and more connected lives as a leading senior fitness and health improvement platform.  This transaction is the culmination of an extensive review of strategic alternatives.  The transaction is scheduled to close in or prior to the third quarter of 2022, subject to the receipt of stockholder approval, regulatory approval and other customary closing conditions.  Following completion of the transaction, Tivity Health will become a privately held company, and its common stock will no longer be traded on Nasdaq.  

 

In light of this pending transaction, the Company will not be hosting an earnings conference call to discuss its results for the quarter and will not be providing or updating previously issued financial guidance.

 

About Tivity Health

 

Tivity Health® Inc. (Nasdaq: TVTY) is a leading provider of healthy life-changing solutions, including SilverSneakers®, Prime® Fitness and WholeHealth Living®. We help adults improve their health and support them on life’s journey by providing access to in-person and virtual physical activity, social, and mental enrichment programs, as well as a full suite of physical medicine and integrative health services. We continue to enhance the way we direct members along their journey to better health by delivering an insights-driven, personalized, interactive experience. Our suite of services support health plans nationwide as they seek to reduce costs and improve health outcomes. At Tivity Health, we deliver the resources members need to live healthier, happier, more connected lives. Learn more at www.tivityhealth.com.

 

Non-GAAP Financial Measures

This press release contains certain non-GAAP financial measures. Reconciliations of certain of these non-GAAP measures to the comparable GAAP measures are included on pages 10-12.

  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain statements that are “forward-looking” statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based upon current expectations and include all statements that are not historical statements of fact and those regarding the intent, belief or expectations, including, without limitation, statements that are accompanied by words such as “will,” “expect,” “outlook,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “would,” “target,” or other similar words, phrases or expressions and variations or negatives of these words. These forward-looking statements include, but are not limited to, the

 

 

 

 


TVTY Reports First Quarter Results

Page 4

May 5, 2022

 

Company’s statements regarding its future financial performance and financial condition. Readers of this press release should understand that these statements are not guarantees of performance or results. Many risks and uncertainties could affect actual results and cause them to vary materially from the forward-looking statements.

 

These risks and uncertainties include, among other things: the risk that the proposed acquisition of the Company (the “Merger”) may not be completed in a timely manner or at all, which may adversely affect the Company’s business and the price of the Company common stock; the failure to satisfy any of the conditions to the consummation of the proposed transaction, including the adoption of the Merger Agreement by the Company’s stockholders and the receipt of certain regulatory approvals; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement, including in circumstances requiring the Company to pay a termination fee; the effect of the announcement or pendency of the proposed transaction on the Company’s business relationships, operating results and business generally; risks that the proposed transaction disrupts the Company’s current plans and operations; the Company’s ability to retain and hire key personnel in light of the proposed transaction; risks related to diverting management’s attention from the Company’s ongoing business operations; unexpected costs, charges or expenses resulting from the proposed transaction; the ability of Stone Point to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Merger; potential litigation relating to the Merger that could be instituted against Stone Point, the Company or their respective directors, managers or officers, including the effects of any outcomes related thereto; continued availability of capital and financing; certain restrictions during the pendency of the Merger that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; impacts from the COVID-19 pandemic (including the response of governmental authorities to combat and contain the pandemic; the development, availability, distribution, and effectiveness of vaccines and treatments, and public confidence in such vaccines and treatments; the closure of fitness centers in the Company’s national network (or operational restrictions imposed on such fitness centers), reclosures, and potential additional reclosures or restrictions as a result of surges in positive COVID-19 cases) on the Company’s business, operations or liquidity; the risks associated with changes in macroeconomic conditions (including the impacts of any recession or changes in consumer spending resulting from the COVID-19 pandemic), widespread epidemics, pandemics (such as the current COVID-19 pandemic, including variant strains of COVID-19) or other outbreaks of disease, geopolitical turmoil, and the continuing threat of domestic or international terrorism; the Company’s ability to collect accounts receivable from its customers and amounts due under its sublease agreements; the market’s acceptance of the Company’s new products and services; the Company’s ability to develop and implement effective strategies and to anticipate and respond to strategic changes, opportunities, and emerging trends in its industry and/or business, as well as to accurately forecast the related impact on its revenues and earnings; the impact of any impairment of the Company’s goodwill, intangible assets, or other long-term assets; changes in fair value of the Company’s equity ownership in Sharecare and the expected timing and amount of cash proceeds from any potential disposition of this holding; the expected timing, amount, and impact of any share repurchases made by the Company; the Company’s ability to attract, hire, or retain key personnel or other qualified employees and to control labor costs; the Company’s ability to effectively compete against other entities, whose financial, research, staff, and marketing resources may exceed the

 

 

 

 


TVTY Reports First Quarter Results

Page 5

May 5, 2022

 

Company’s resources; the impact of legal proceedings involving the Company and/or its subsidiaries, products, or services, including any claims related to intellectual property rights, as well as the Company’s ability to maintain insurance coverage with respect to such legal proceedings and claims on terms that would be favorable to the Company; the impact of severe or adverse weather conditions, the current COVID-19 pandemic (including variant strains of COVID-19), and the potential emergence of additional health pandemics or infectious disease outbreaks on member participation in the Company’s programs; the risks associated with the Company deriving a significant concentration of its revenues from a limited number of our customers, many of whom are health plans; the Company’s ability and/or the ability of its customers to enroll participants and to accurately forecast their level of enrollment and participation in its programs in a manner and within the timeframe it anticipates; the Company’s ability to sign, renew and/or maintain contracts with its customers and/or its fitness partner locations under existing terms or to restructure these contracts on terms that would not have a material negative impact on the Company’s results of operations; the ability of the Company’s health plan customers to maintain the number of covered lives enrolled in those health plans during the terms of the Company’s agreements; the Company’s ability to add and/or retain active subscribers in its Prime Fitness program; the impact of any changes in tax rates, enactment of new tax laws, revisions of tax regulations, or any claims or litigation with taxing authorities; the impact of a reduction in Medicare Advantage health plan reimbursement rates or changes in plan design; the impact of any new or proposed legislation, regulations and interpretations relating to Medicare, Medicare Advantage, Medicare Supplement and privacy and security laws; the impact of healthcare reform on the Company’s business; the risks associated with increased focus from investors and other stakeholders regarding ESG practices, which could result in additional costs, regulation, or risks and adversely impact the Company’s reputation, employee recruiting and retention, and willingness of customers and suppliers to do business with the Company; the risks associated with potential failures of the Company’s information systems or those of its third-party vendors, including as a result of telecommuting issues associated with personnel working remotely, which may include a failure to execute on policies and processes in a work-from-home or remote model; the risks associated with data privacy or security breaches, computer hacking, network penetration and other illegal intrusions of the Company’s information systems or those of third-party vendors or other service providers, including those risks that result from the increase in personnel working remotely, which may result in unauthorized access by third parties, loss, misappropriation, disclosure or corruption of customer, employee or our information, or other data subject to privacy laws and may lead to a disruption in the Company’s business, costs to modify, enhance, or remediate its cybersecurity measures, enforcement actions, fines or litigation against the Company, or damage to its business reputation; the risks associated with changes to traditional office-centered business processes and/or conducting operations out of the office in a work-from-home or remote model by the Company or its third-party vendors during adverse situations (e.g., during a crisis, disaster, or pandemic), which may result in additional costs and/or may negatively impact productivity and cause other disruptions to the Company’s business; the Company’s ability to enforce its intellectual property rights; the risk that the Company’s indebtedness may limit its ability to adapt to changes in the economy or market conditions, expose it to interest rate risk for the variable rate indebtedness and require a substantial portion of cash flows from operations to be dedicated to the payment of indebtedness; the Company’s ability to service its debt, make principal and interest payments as those payments become due, and remain in compliance with its debt covenants; the Company’s ability to obtain adequate financing to provide the capital that

 

 

 

 


TVTY Reports First Quarter Results

Page 6

May 5, 2022

 

may be necessary to support its current or future operations; counterparty risk associated with the Company’s interest rate swap agreements and changes in fair value of certain interest rate swap agreements that no longer qualify for hedge accounting treatment; and other risks detailed in the Company’s filings with the Securities and Exchange Commission.

 

For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company’s filings with the SEC. Except as required by law, the Company undertakes no obligation to update any such forward-looking statements to reflect new information, subsequent events or circumstances.

 

Additional Information and Where to Find It

 

In connection with the Merger, the Company intends to file a preliminary proxy statement on Schedule 14A with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, COMPANY

STOCKHOLDERS ARE URGED TO READ THE PRELIMINARY PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS, INCLUDING THE DEFINITIVE PROXY STATEMENT (IF AND WHEN IT BECOMES AVAILABLE), THAT ARE FILED OR WILL BE FILED WITH THE SEC (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER. The definitive proxy statement (if and when it becomes available) will be mailed to stockholders of the Company. Stockholders will be able to obtain the documents (if and when they become available) free of charge at the SEC’s website, http://www.sec.gov. In addition, stockholders may obtain free copies of the documents (if and when they become available) on the Company’s website, www.tivityhealth.com, under the heading “Investors.”

 

Participants in the Solicitation

 

The Company and certain of its directors, executive officers and other employees, under the SEC’s rules, may be deemed to be participants in the solicitation of proxies of the Company’s stockholders in connection with the Merger. Additional information regarding the interests of those participants and other persons who may be deemed participants in the Merger and their respective direct and indirect interests in the Merger, by security holdings or otherwise, will be included in the definitive proxy statement and other materials to be filed with the SEC in connection with the Merger (if and when they become available). Free copies of these documents may be obtained as described in the preceding paragraph.

 

Investor Relations Contact:

 

Matt Milanovich, VP, Investor Relations and FP&A; (602) 562-2595; matt.milanovich@tivityhealth.com


 

 

 

 


TVTY Reports First Quarter Results

Page 7

May 5, 2022

 

 

TIVITY HEALTH, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited) 

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

92,076

 

 

$

60,132

 

Accounts receivable, net

 

 

58,011

 

 

 

62,730

 

Prepaid expenses

 

 

5,420

 

 

 

6,465

 

Income taxes receivable

 

 

 

 

 

3,095

 

Investment in equity securities

 

 

27,366

 

 

 

49,746

 

Other current assets

 

 

8,308

 

 

 

13,733

 

Total current assets

 

 

191,181

 

 

 

195,901

 

 

 

 

 

 

 

 

 

 

Property and equipment, net of accumulated depreciation of

   $47,280 and $44,229, respectively

 

 

25,721

 

 

 

25,247

 

Right-of-use assets

 

 

8,811

 

 

 

10,695

 

Intangible assets, net

 

 

29,049

 

 

 

29,049

 

Goodwill, net

 

 

334,680

 

 

 

334,680

 

Other assets

 

 

5,723

 

 

 

2,969

 

Total assets

 

$

595,165

 

 

$

598,541

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

25,376

 

 

$

25,325

 

Accrued salaries and benefits

 

 

4,065

 

 

 

11,825

 

Accrued liabilities

 

 

31,624

 

 

 

28,270

 

Deferred revenue

 

 

3,201

 

 

 

3,371

 

Income taxes payable

 

 

2,774

 

 

 

 

Current portion of lease liabilities

 

 

7,388

 

 

 

8,007

 

Current portion of other long-term liabilities

 

 

2,832

 

 

 

10,625

 

Total current liabilities

 

 

77,260

 

 

 

87,423

 

 

 

 

 

 

 

 

 

 

Long-term debt

 

 

379,960

 

 

 

380,504

 

Long-term lease liabilities

 

 

2,072

 

 

 

3,487

 

Long-term deferred tax liability

 

 

7,789

 

 

 

3,183

 

Other long-term liabilities

 

 

137

 

 

 

5,037

 

 

 

 

 

 

 

 

 

 

Commitments and contingent liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Preferred stock $.001 par value, 5,000,000 shares authorized,

   none outstanding

 

 

 

 

 

 

Common Stock $.001 par value, 120,000,000 shares authorized,

   49,854,631 and 49,800,756 shares outstanding, respectively

 

 

50

 

 

 

50

 

Additional paid-in capital

 

 

516,113

 

 

 

514,461

 

Accumulated deficit

 

 

(358,590

)

 

 

(359,171

)

Treasury stock, at cost, 2,254,953 shares in treasury

 

 

(28,182

)

 

 

(28,182

)

Accumulated other comprehensive loss

 

 

(1,444

)

 

 

(8,251

)

Total stockholders' equity

 

 

127,947

 

 

 

118,907

 

Total liabilities and stockholders' equity

 

$

595,165

 

 

$

598,541

 

 

 

 

 

 


TVTY Reports First Quarter Results

Page 8

May 5, 2022

 

 

TIVITY HEALTH, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except earnings per share data)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

 

2022

 

 

2021

 

 

Revenues

 

$

127,513

 

 

$

108,085

 

 

Cost of revenue (exclusive of depreciation of $3,065 and $2,531,

   respectively included below)

 

 

78,415

 

 

 

57,285

 

 

Marketing expense

 

 

2,784

 

 

 

1,231

 

 

Selling, general and administrative expenses

 

 

10,700

 

 

 

9,696

 

 

Depreciation expense

 

 

3,206

 

 

 

2,683

 

 

Operating income

 

 

32,408

 

 

 

37,190

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

6,993

 

 

 

10,756

 

 

Other (income) expense, net

 

 

16,685

 

 

 

(1,130

)

 

Total non-operating expense, net

 

 

23,678

 

 

 

9,626

 

 

Income before income taxes

 

 

8,730

 

 

 

27,564

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

8,086

 

 

 

7,620

 

 

Income from continuing operations

 

$

644

 

 

$

19,944

 

 

 

 

 

 

 

 

 

 

 

 

Loss from discontinued operations, net of income tax benefit of $21

   and $277, respectively

 

 

(63

)

 

 

(808

)

 

Net income

 

$

581

 

 

$

19,136

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share - basic:

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

0.01

 

 

$

0.41

 

 

Discontinued operations

 

$

(0.00

)

 

$

(0.02

)

 

Net income

 

$

0.01

 

 

$

0.39

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share - diluted:

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

0.01

 

 

$

0.40

 

 

Discontinued operations

 

$

(0.00

)

 

$

(0.02

)

 

Net income

 

$

0.01

 

 

$

0.38

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income

 

$

7,388

 

 

$

21,938

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares and equivalents:

 

 

 

 

 

 

 

 

 

Basic

 

 

49,838

 

 

 

49,222

 

 

Diluted

 

 

50,557

 

 

 

50,340

 

 

 

 

 

 

 

 


TVTY Reports First Quarter Results

Page 9

May 5, 2022

 

 

TIVITY HEALTH, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Income from continuing operations

 

$

644

 

 

$

19,944

 

Loss from discontinued operations

 

 

(63

)

 

 

(808

)

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

3,206

 

 

 

2,683

 

Amortization and write-off of deferred loan costs

 

 

492

 

 

 

1,183

 

Amortization and write-off of debt discount

 

 

63

 

 

 

1,077

 

Share-based employee compensation expense

 

 

1,919

 

 

 

2,998

 

Unrealized gain on derivatives

 

 

(5,695

)

 

 

(1,130

)

Unrealized loss on investments in equity securities

 

 

22,380

 

 

 

 

Deferred income taxes

 

 

2,272

 

 

 

1,454

 

Decrease (increase) in accounts receivable, net

 

 

4,719

 

 

 

(18,978

)

Changes in income taxes receivable and payable

 

 

5,869

 

 

 

10,217

 

Decrease in other current assets

 

 

1,992

 

 

 

529

 

Decrease in accounts payable

 

 

(945

)

 

 

(42

)

Decrease in accrued salaries and benefits

 

 

(7,760

)

 

 

(3,685

)

Increase in other current liabilities

 

 

7,553

 

 

 

5,594

 

Other

 

 

369

 

 

 

1,582

 

Net cash flows provided by operating activities

 

$

37,015

 

 

$

22,618

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Acquisition of property and equipment

 

$

(2,715

)

 

$

(1,561

)

Settlement on derivatives not designated as hedges

 

 

(1,390

)

 

 

(1,633

)

Net cash flows used in investing activities

 

$

(4,105

)

 

$

(3,194

)

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Payments of long-term debt

 

 

(1,000

)

 

 

(63,600

)

Payments related to tax withholding for share-based compensation

 

 

(472

)

 

 

(2,502

)

Exercise of stock options

 

 

205

 

 

 

164

 

Change in cash overdraft and other

 

 

301

 

 

 

(1,443

)

Net cash flows used in financing activities

 

$

(966

)

 

$

(67,381

)

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

$

31,944

 

 

$

(47,957

)

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

$

60,132

 

 

$

100,385

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, end of period

 

$

92,076

 

 

$

52,428

 

 


 

 

 

 


TVTY Reports First Quarter Results

Page 10

May 5, 2022

 

 

TIVITY HEALTH, INC.
RECONCILIATION OF NON-GAAP MEASURES TO GAAP MEASURES
(Unaudited)

 

Reconciliation of Income from Continuing Operations, GAAP Basis to

Adjusted EBITDA from Continuing Operations, Non-GAAP Basis (in thousands)

 

 

 

 

Three Months Ended March 31, 2022

 

% of Revenue

 

 

Three Months Ended March 31, 2021

 

 

% of Revenue

 

Income from continuing operations, GAAP basis

 

$

644

 

0.5%

 

 

19,944

 

 

18.5%

 

Income tax expense

 

 

8,086

 

 

 

 

7,620

 

 

 

 

Interest expense

 

 

6,993

 

 

 

 

10,756

 

 

 

 

Depreciation expense

 

 

3,206

 

 

 

 

2,683

 

 

 

 

EBITDA from continuing operations, non-GAAP basis (1)

 

$

18,929

 

 

 

$

41,003

 

 

 

 

Integration, project, and CEO transition costs (2)

 

 

1,737

 

 

 

 

1,321

 

 

 

 

Other (income) expense, net (3)

 

 

16,685

 

 

 

 

(1,130

)

 

 

 

Adjusted EBITDA from continuing operations, non-GAAP basis (4)

 

$

37,351

 

29.3%

 

$

41,194

 

 

38.1%

 

 

 

(1)

EBITDA from continuing operations is a non-GAAP financial measure.  The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management.  You should not consider EBITDA from continuing operations in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP.

 

(2)

Integration, project, and CEO transition costs consist of pre-tax charges of $1,737 and $1,321 for the three months ended March 31, 2022 and 2021, respectively, primarily incurred in connection with strategic projects (including the potential Merger) and with the termination of the Company’s former CEO in February 2020 and the hiring of its new CEO in June 2020.

 

(3)

Other (income) expense consists of pre-tax expense of $16,685 and pre-tax income of ($1,130) for the three months ended March 31, 2022 and 2021, respectively, related to (i) unrealized losses on the Company’s equity ownership in Sharecare during the first quarter of 2022, and (ii) unrealized gains on certain interest rate swap agreements that no longer qualify for hedge accounting treatment (“de-designated swaps”) and require changes in fair value to be recognized each period in current earnings.

 

(4)

Adjusted EBITDA from continuing operations is a non-GAAP financial measure.  The Company excludes integration, project, and CEO transition costs and other (income) expense from this measure because of its comparability to the Company's historical operating results.  The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management.  You should not consider Adjusted EBITDA from continuing operations in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP.  Additionally, because Adjusted EBITDA from continuing operations may be defined differently by other companies in the Company’s industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies.

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 


TVTY Reports First Quarter Results

Page 11

May 5, 2022

 

 

Reconciliation of Net Cash Flows Provided by Operating Activities, GAAP Basis to

Free Cash Flow, Non-GAAP Basis (in thousands)

 

 

 

 

 

 

Three Months

Ended

March 31,

2022

 

 

 

Three Months

Ended

March 31,

2021

 

Net cash flows provided by operating activities, GAAP basis

 

 

 $

37,015

 

 

 $

22,618

 

Acquisition of property and equipment

 

 

 

(2,715

)

 

 

(1,561

)

Settlement on derivatives not designated as hedges

 

 

 

(1,390

)

 

 

(1,633

)

Free cash flow, non-GAAP basis (5)

 

 

$

32,910

 

 

$

19,424

 

 

 

 

 

 

 

 

 

 

 

 

 

(5)

Free cash flow is a non-GAAP financial measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment and settlement on derivatives not designated as hedges.  The Company believes free cash flow is a useful measure of performance, an indication of the strength of the Company and its ability to generate cash, and the amount of cash that is available to repay debt or make other investments.  The Company believes it is useful to investors to provide disclosures of its results on the same basis as that used by management.  You should not consider free cash flow in isolation or as a substitute for net cash flows provided by operating activities determined in accordance with U.S. GAAP. Additionally, because free cash flow may be defined differently by other companies in the Company’s industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies.

 

 

Reconciliation of Diluted Earnings Per Share (“EPS”) from Continuing Operations, GAAP Basis to

Adjusted EPS from Continuing Operations, Non-GAAP Basis (footnote amounts in thousands)

 

 

 

 

 

Three Months

Ended

March 31,

2022

 

 

Three Months

Ended

March 31,

2021

 

 

 

EPS from continuing operations, GAAP basis

 

 $

0.01

 

 $

0.40

 

 

 

   Net loss attributable to integration, project, and CEO transition costs (6)

 

 

0.03

 

 

0.02

 

 

 

   Net income per share attributable to other (income) expense, net (7)

 

 

0.36

 

 

(0.02

)

 

 

Adjusted EPS from continuing operations, GAAP basis (8)

 

$

0.40

 

$

0.40

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6)

Net loss attributable to integration, project, and CEO transition costs consists of pre-tax charges of $1,737 and $1,321 for the three months ended March 31, 2022 and 2021, respectively, primarily incurred in connection with strategic projects (including the potential Merger) and with the termination of the Company’s former CEO in February 2020 and the hiring of its new CEO in June 2020. The tax rate applied to these charges was 25%, which represented the combined estimated U.S. federal and state statutory tax rate.

 

(7)

Net income attributable to other (income) expense consists of pre-tax expense of $16,685 and pre-tax income of ($1,130) for the three months ended March 31, 2022 and 2021, respectively, related to the Company’s equity ownership in Sharecare and unrealized gains on the Company’s de-designated swaps, as described in Note 3 above.  The tax rate applied to the income related to the de-designated swaps was 25%, which represented the combined estimated U.S. federal and state statutory tax rate. There is no net tax impact on the loss related to the Company’s equity ownership in Sharecare due to the existence of valuation allowances for deferred tax assets related to capital loss carryforwards.

 

(8)

Adjusted EPS from continuing operations is a non-GAAP financial measure.  The Company excludes net (income) loss per share attributable to integration, project, and CEO transition costs and other (income) expense from this measure because of its comparability to the Company's historical operating results.  The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management.  You should not consider adjusted EPS from continuing operations in isolation or as a substitute for EPS from continuing

 

 

 

 


TVTY Reports First Quarter Results

Page 12

May 5, 2022

 

 

operations determined in accordance with U.S. GAAP.  Additionally, because adjusted EPS from continuing operations may be defined differently by other companies in the Company’s industry, the non-GAAP financial measures presented here may not be comparable to similarly titled measures of other companies. Figures may not add due to rounding.

 

 

 

 

 

 

GRAPHIC 3 gn5lxo3ez5nd000001.jpg GRAPHIC begin 644 gn5lxo3ez5nd000001.jpg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tvty-20220505.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 tvty-20220505_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 tvty-20220505_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 05, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 05, 2022
Entity Registrant Name TIVITY HEALTH, INC.
Entity Central Index Key 0000704415
Entity Emerging Growth Company false
Entity File Number 000-19364
Entity Incorporation State Country Code DE
Entity Tax Identification Number 62-1117144
Entity Address, Address Line One 701 Cool Springs Boulevard
Entity Address, City or Town Franklin
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37067
City Area Code (800)
Local Phone Number 869-5311
Written Communications false
Soliciting Material true
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock - $.001 par value
Trading Symbol TVTY
Security Exchange Name NASDAQ
XML 8 tvty-8k_20220505_htm.xml IDEA: XBRL DOCUMENT 0000704415 2022-05-05 2022-05-05 false 0000704415 8-K 2022-05-05 TIVITY HEALTH, INC. DE 000-19364 62-1117144 701 Cool Springs Boulevard Franklin TN 37067 (800) 869-5311 false true false false Common Stock - $.001 par value TVTY NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports tvty-8k_20220505.htm tvty-20220505.xsd tvty-20220505_lab.xml tvty-20220505_pre.xml tvty-ex991_33.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tvty-8k_20220505.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tvty-8k_20220505.htm" ] }, "labelLink": { "local": [ "tvty-20220505_lab.xml" ] }, "presentationLink": { "local": [ "tvty-20220505_pre.xml" ] }, "schema": { "local": [ "tvty-20220505.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tvty", "nsuri": "http://www.tivityhealth.com/20220505", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tvty-8k_20220505.htm", "contextRef": "C_0000704415_20220505_20220505", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tvty-8k_20220505.htm", "contextRef": "C_0000704415_20220505_20220505", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "verboseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tivityhealth.com/20220505/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-22-018279-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-018279-xbrl.zip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end